Unresectable Locally Advanced Clinical Trials

10 recruitingLast updated: June 17, 2026

There are 10 actively recruiting unresectable locally advanced clinical trials across 4 countries. Studies span Phase 2, Phase 1, Phase 3. Top locations include Shanghai, Shanghai Municipality, China, Shenzhen, Guangdong, China, Baltimore, Maryland, United States. Updated daily from ClinicalTrials.gov.


Unresectable Locally Advanced Trials at a Glance

10 actively recruiting trials for unresectable locally advanced are listed on ClinicalTrialsFinder across 6 cities in 4 countries. The largest study group is Phase 2 with 9 trials, with the heaviest enrollment activity in Shanghai, Shenzhen, and Baltimore. Lead sponsors running unresectable locally advanced studies include Beijing Biotech, Criterium, Inc., and Brenus Pharma.

Browse unresectable locally advanced trials by phase

Treatments under study

About Unresectable Locally Advanced Clinical Trials

Looking for clinical trials for Unresectable Locally Advanced? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Unresectable Locally Advanced trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Unresectable Locally Advanced clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 110 of 10 trials

Recruiting
Phase 1Phase 2

Dual-Target CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma

Pancreatic Ductal Adenocarcinoma (PDAC)Metastatic DiseaseUnresectable Locally Advanced
Beijing Biotech42 enrolled1 locationNCT07627711
Recruiting
Phase 2

Tucatinib+Trastuzumab+Eribulin in HER2+ MBC

Breast CancerPretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Cancer
Criterium, Inc.30 enrolled6 locationsNCT05458674
Recruiting
Phase 1Phase 2

Dual-Targeting CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma

Pancreatic Ductal Adenocarcinoma (PDAC)Unresectable Locally Advanced or Metastatic Disease
Beijing Biotech42 enrolled1 locationNCT07480928
Recruiting
Phase 3

A Phase III Study of SHR-A1811 in Combination With Chemotherapy and Adebrelimab in Previously Untreated Patients With Gastric or Gastroesophageal Junction Adenocarcinoma

Patients With Unresectable Locally Advanced or Metastatic Untreated Gastric or Gastroesophageal Junction Adenocarcinoma
Suzhou Suncadia Biopharmaceuticals Co., Ltd.600 enrolled2 locationsNCT07118527
Recruiting
Phase 1Phase 2

IBI3014 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors

Unresectable Locally Advanced or Metastatic Solid Tumors
Innovent Biologics (Suzhou) Co. Ltd.250 enrolled3 locationsNCT06974812
Recruiting
Phase 1Phase 2

Phase I/II Clinical Study of JMT108 Injection for the Treatment of Advanced Malignant Melanoma

Unresectable Locally Advanced or Metastatic Melanoma
Shanghai JMT-Bio Inc.188 enrolled1 locationNCT07280832
Recruiting
Phase 1Phase 2

First-in-human Trial of STC-1010, an Immunotherapy, in Patients With Unresectable Locally Advanced or Metastatic Colorectal Cancer

Unresectable Metastatic Colorectal CancerUnresectable Locally Advanced Colorectal Cancer
Brenus Pharma90 enrolled9 locationsNCT06934538
Recruiting
Phase 2

A Single-arm, Open-label, Single-center Prospective Study of Fruquintinib Combined With Envafolimab in the Treatment of Advanced or Unresectable Locally Advanced Bone and Soft Tissue Sarcoma

Advanced or Unresectable Locally Advanced Bone and Soft Tissue Sarcoma
Shanghai 6th People's Hospital20 enrolled1 locationNCT05941325
Recruiting
Phase 1Phase 2

TSN222 in Subjects With Advanced Solid Tumors or Lymphomas

Has a Pathologically Documented Unresectable Locally Advanced or Metastatic Solid Tumor or Lymphoma
Tyligand Bioscience (Shanghai) Limited162 enrolled1 locationNCT05842785
Recruiting
Phase 1Phase 2

Immunotherapy in Combination With Chemoradiotherapy in Unresectable Locally Advanced Esophageal Cancer

Esophageal Squamous Cell CarcinomaUnresectable Locally Advanced Esophageal Cancer
Shanghai Chest Hospital50 enrolled1 locationNCT06173986